SEC
SlamSEC
SearchBrowseEarnings

CureVac N.V.

Nasdaq:CVAC
Pharmaceutical Preparations·TUBINGEN
OverviewAll FilingsSum FinCreditInsidersGovernance
OverviewAll FilingsSum FinCreditInsidersGovernance

All Filings(274 total)

TypeDateAccessionPeriodSize
15-12G
Jan 16, 2026
0001193125-26-01466315-12G
—
11.7 KB
S-8 POS
Jan 7, 2026
0001193125-26-006332S-8 POS
—
19.1 KB
25-NSE
Jan 6, 2026
0001354457-26-000010
—
3.2 KB
6-K
Jan 6, 2026
0001193125-26-0033876-K
Jan 6, 2026
11.7 KB
SC TO-T/A
Dec 18, 2025
0001193125-25-324846SC TO-T/A
—
21.7 KB
SC 14D9/A
Dec 18, 2025
0001104659-25-122532SC 14D9/A
—
19.8 KB
SCHEDULE 13D/A
Dec 12, 2025
0001213900-25-121266
—
9.4 KB
SCHEDULE 13D/A
Dec 12, 2025
0001213900-25-121173
—
19.5 KB
SCHEDULE 13D/A
Dec 12, 2025
0001140361-25-045338
—
10.8 KB
SCHEDULE 13D/A
Dec 5, 2025
0001999371-25-019650
—
31.1 KB
SC 14D9/A
Dec 5, 2025
0001104659-25-118724SC 14D9/A
—
16.2 KB
SC TO-T/A
Dec 3, 2025
0001193125-25-306859SC TO-T/A
—
24.1 KB
425
Dec 3, 2025
0001193125-25-306796425
—
43.9 KB
SC TO-T/A
Nov 26, 2025
0001193125-25-300729SC TO-T/A
—
22.1 KB
425
Nov 26, 2025
0001193125-25-300674425
—
45.5 KB
SC 14D9/A
Nov 26, 2025
0001104659-25-116277SC 14D9/A
—
17.7 KB
6-K
Nov 26, 2025
0001104659-25-116274FORM 6-K
Nov 26, 2025
61.0 KB
SC 14D9/A
Nov 25, 2025
0001104659-25-115771SC 14D9/A
—
357.4 KB
SC 14D9/A
Nov 24, 2025
0001104659-25-115235SC 14D9/A
—
22.6 KB
6-K
Nov 24, 2025
0001104659-25-115210FORM 6-K
Nov 24, 2025
167.0 KB
425
Nov 12, 2025
0001193125-25-276015425
—
857.4 KB
425
Nov 12, 2025
0001193125-25-276012425
—
835.6 KB
6-K
Oct 27, 2025
0001104659-25-102252FORM 6-K
Oct 24, 2025
472.5 KB
SC 14D9/A
Oct 23, 2025
0001104659-25-101637SC 14D9/A
—
35.2 KB
SC 14D9/A
Oct 22, 2025
0001104659-25-101584SC 14D9/A
—
307.2 KB
25 filings shown

CureVac is a biopharmaceutical company based in Tübingen, Germany that develops therapies based on messenger RNA (mRNA). With approximately 375 employees in 2018, it was founded in 2000 by Ingmar Hoerr, Steve Pascolo, Florian von der Mulbe, Günther Jung, and Hans-Georg Rammensee.